



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Date: 26th August 2019

Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051
Symbol : BAFNAPHARM Series : EQ

Dear Sir,

Sub.:- Clarification of Financial Result for the quarter ending 30th June 2019

With reference to email regarding deficiency in financial result, Please find attached result as per format prescribed by SEBI.

Please take it on record.

Thanking you.

Yours faithfully,
For BAFNA PHARMACEUTICALS LIMITED

Jitendra Kumar Pal
Company Secretary



BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd Office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30 th June 2019

STANDALONE

CONSOLIDATED

PART I	Sl.No	Particulars	3 months ended (06-2019) standalone		Preceding 3 months ended (03-2019) standalone		Corresponding 3 months ended (31-06-2018) standalone		For the Previous Year ended (31.03.2019) standalone		Consolidated Upto 3 months ended (30.06.2019)		Consolidated Upto 3 months ended (31.03.2019)		Consolidated Upto 3 months ended (30.06.2018)		Consolidated For the Previous Year ended (31.03.2019)	
			Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
I		Revenue From operations	684.93	949.48	1,195.13	4,335.89	684.93	949.48	1,195.13	4,335.89	684.93	949.48	1,195.13	4,335.89	684.93	949.48	1,195.13	4,335.89
II		Other Income	30.17	27.62	9.19	65.36	30.17	27.62	9.19	65.36	30.17	27.62	9.19	65.36	30.17	27.62	9.19	65.36
III		Total Income (I+II)	715.09	977.10	1,204.31	4,401.25	715.09	977.10	1,204.31	4,401.25	715.09	977.10	1,204.31	4,401.25	715.09	977.10	1,204.31	4,401.25
IV		EXPENSES																
a)		Cost of materials consumed	594.61	742.04	1,093.80	3,329.44	594.61	742.04	1,093.80	3,329.44	594.61	742.04	1,093.80	3,329.44	594.61	742.04	1,093.80	3,329.44
b)		Purchases of Stock-in-Trade	-	15.68	15.00	46.36	-	15.68	15.00	46.36	-	15.68	15.00	46.36	-	15.68	15.00	46.36
c)		Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	(60.34)	139.24	(5.08)	81.14	(60.34)	139.24	(5.08)	81.14	(60.34)	139.24	(5.08)	81.14	(60.34)	139.24	(5.08)	81.14
d)		Employee benefits expense	231.49	267.08	194.31	901.29	231.49	267.08	194.31	901.29	231.49	267.08	194.31	901.29	231.49	267.08	194.31	901.29
e)		Finance costs	12.68	21.16	83.21	342.17	12.68	21.16	83.21	342.17	12.68	21.16	83.21	342.17	12.68	21.16	83.21	342.17
f)		Depreciation and amortization expenses	101.78	76.72	100.00	212.64	101.78	76.72	100.00	212.64	101.78	76.72	100.00	212.64	101.78	76.72	100.00	212.64
g)		Other expenses	105.84	1,065.43	78.56	1,311.18	105.84	1,065.43	78.56	1,311.18	105.84	1,065.43	78.56	1,311.18	105.84	1,065.43	78.56	1,311.18
		Total expenses (IV)	1,086.06	2,327.35	1,559.81	6,224.22	1,086.06	2,327.35	1,559.81	6,224.22	1,086.06	2,327.35	1,559.81	6,224.22	1,086.06	2,327.35	1,559.81	6,224.22
V		Profit/(loss) before exceptional items and tax (I-IV)	(370.96)	(1,350.25)	(355.50)	(1,822.97)	(370.96)	(1,350.25)	(355.50)	(1,822.97)	(370.96)	(1,350.25)	(355.50)	(1,822.97)	(370.96)	(1,350.25)	(355.50)	(1,822.97)
VI		Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
VII		Profit/(loss) before exceptions items and tax (V+VI)	(370.96)	(1,350.25)	(355.50)	(1,822.97)	(370.96)	(1,350.25)	(355.50)	(1,822.97)	(370.96)	(1,350.25)	(355.50)	(1,822.97)	(370.96)	(1,350.25)	(355.50)	(1,822.97)
VIII		Tax expense:	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		(1) Current tax	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		(2) Deferred tax	(158.21)	149.36	(4.19)	150.07	(158.21)	149.36	(4.19)	150.07	(158.21)	149.36	(4.19)	150.07	(158.21)	149.36	(4.19)	150.07
IX		Profit/(loss) for the period from continuing operations (VII-VIII)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)
X		Profit/(loss) from discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XI		Tax expenses of discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XII		Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XIII		Profit/(loss) for the period (IX+XII)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)
		Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XIV		(i) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		(iii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XV		Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other Comprehensive Income for the period	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)	(212.75)	(1,499.61)	(351.31)	(1,973.04)
XVI		Earnings per equity share (for continuing operation):																
		(1) Basic	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)
		(2) Diluted	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)
XVII		Earnings per equity share (for discontinued operation):																
		(1) Basic	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
		(2) Diluted	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
XVIII		Earnings per equity share (for discontinued & continuing operation)																
		(1) Basic	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)
		(2) Diluted	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)	(0.90)	(6.34)	(1.49)	(8.34)

1. The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 10.08.2019

2. The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.

3. The above figures have been regrouped and Re-arranged Wherever considered necessary

4. Being the First Quarter of the year, Figures of the Quarter ended 30th June 2019 and Year to date for this Quarter are same hence not mentioned separately.

For BAFNA PHARMACEUTICALS LIMITED



(Signature)
MANAGING DIRECTOR

(BAFNA MAHAVEER CHAND)
MANAGING DIRECTOR
DIN:01458211

Place: Chennai
Date: 10.08.2019